Vivos Therapeutics, Inc. (NASDAQ: VVOS) had its "buy" rating re-affirmed by analysts at Ascendiant Capital Markets. They now have a $6.60 price target on the stock.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) had its price target lowered by analysts at Alliance Global Partners from $8.25 to $6.00. They now have a "buy" rating on the stock.
Vivos Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update [Yahoo! Finance]
Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update